Janssen Pharmaceuticals, Inc., a company blamed for antipsychotic drug injuries allegedly sustained by plaintiffs in hundreds of Risperdal lawsuit claims, has launched a new program to improve global health around the world.

According to a Jan. 22nd article from 4-Traders.com, Janssen Global Public Health (Janssen GPH) will lead research and product development  for creating new access strategies for medicines and services in countries with limited resources, among other things.

“To solve today’s greatest public health challenges, it’s essential that we emphasize the needs of the developing world in equal measure to those of the developed world,” said the Chief Scientific Officer of Johnson & Johnson and Worldwide Chairman of Janssen.

Officials say the new program will also work to make medicines more affordable in emerging markets, and create long-term solutions for those patients. It will also build off Janssen’s Global Access and Partnerships Program (GAPP), which is geared towards ensuring that individuals in under-developed countries receive access to the company’s HIV medicines.

Janssen Touts New Program after $2.5 Million Risperdal Lawsuit Settlement

News of Janssen’s recent patient-centered efforts come as the smoke begins to clear on a controversial Risperdal settlement that charged its parent company, Johnson & Johnson more than $2.5 million in damages after accusations from the federal government that the medication was promoted for off-label uses not approved by the U.S. Food and Drug Administration (FDA).

According to the agreement reached in November 2013, Risperdal was marketed to elderly patients with dementia and for use in children long before it was approved for pediatric uses in 2006.

The medication, which is prescribed to adults and adolescents with schizophrenia and bipolar disorder, is also frequently used to treat irritability in children with autism.

Side effects associated with Risperdal have also resulted in many personal injury and product liability lawsuits against Janssen and Johnson & Johnson. According to court documents, more than 200 cases have been filed in a consolidated litigation established in Pennsylvania’s Philadelphia Court of Common Pleas on behalf of individuals who may have suffered side effects caused by the medication. Many of these lawsuits allege Risperdal gynecomastia, a painful and unpleasant complication categorized by male breast growth.

Contact a Risperdal Lawyer Today

At Bernstein Liebhard LLP, a Risperdal lawyer is standing by to answer any legal questions you have about filing a lawsuit over the anti-psychotic medication. The Firm can be reached at (877) 779-1414.

Published January 28, 2014 by